表紙
市場調査レポート

ピーナッツ・アレルギー : パイプライン分析

Peanut Allergy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251569
出版日 ページ情報 英文 87 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ピーナッツ・アレルギー : パイプライン分析 Peanut Allergy - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 87 Pages
概要

ピーナッツ・アレルギーは特に子どもによく見られます。 ピーナッツへのアレルギー反応は、通常摂取後数分内に起こり、症状は軽度なものから重度のものまで分かれます。 ピーナッツ・アレルギーの兆候および症状は、口および喉周辺にじんましんや赤くなったりむくんだり、かゆかったりヒリヒリしたり、下痢、胃痙攣、吐き気あるいは嘔吐のような消化器官の問題が起きたり、喉が締まったり、息切れあるいは息がぜいぜい音を立てたり、鼻水が出たりします。

当レポートでは、ピーナッツ・アレルギーの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ピーナッツ・アレルギー 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • BioLingus AG
  • BioTech Tools s.a.
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • aldesleukin
  • ピーナッツ・アレルギーのアレルゲン
  • AR-101
  • ARA-LAMP-Vax
  • DBV-712
  • DN-1017
  • ピーナッツ・アレルギー/喘息向け CYP11A1 阻害薬
  • 呼吸器系・ 免疫疾患向け PIM-1 キナーゼ阻害薬
  • PER-1080
  • pnut-ASIT
  • ピーナッツ・アレルギー向け組み換えタンパク質
  • ピーナッツ・アレルギー 向け組み換えベクターワクチン
  • VTC-064

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7886IDB

Summary

Global Markets Direct's, 'Peanut Allergy - Pipeline Review, H1 2016', provides an overview of the Peanut Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peanut Allergy
  • The report reviews pipeline therapeutics for Peanut Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peanut Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Peanut Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peanut Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peanut Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peanut Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Peanut Allergy - Overview
    • Pipeline Products for Peanut Allergy - Comparative Analysis
  • Peanut Allergy - Therapeutics under Development by Companies
  • Peanut Allergy - Therapeutics under Investigation by Universities/Institutes
  • Peanut Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Peanut Allergy - Products under Development by Companies
  • Peanut Allergy - Products under Investigation by Universities/Institutes
  • Peanut Allergy - Companies Involved in Therapeutics Development
    • Aimmune Therapeutics, Inc.
    • AnaptysBio, Inc.
    • Array BioPharma Inc.
    • ASIT biotech s.a.
    • BioLingus AG
    • DBV Technologies S.A.
    • HAL Allergy BV
    • Immunomic Therapeutics, Inc.
  • Peanut Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANB-020 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AR-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AR-460770 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-0892 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DBV-712 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PER-1080 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pnut-ASIT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SCV-209 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTC-064 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Peanut Allergy - Recent Pipeline Updates
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 11, 2016: Aimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101
      • Mar 06, 2016: Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance
      • Mar 06, 2016: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance
      • Mar 04, 2016: DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy
      • Mar 01, 2016: Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy
      • Feb 25, 2016: DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology Supporting Safety and Tolerability of Viaskin Peanut
      • Feb 10, 2016: DBV Technologies to Present New Data on Viaskin Peanut Allergy at the 2016 AAAAI Annual Meeting
      • Jan 11, 2016: Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
      • Dec 07, 2015: DBV Technologies Announces Initiation of Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children
      • Nov 11, 2015: Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peanut Allergy, H1 2016
  • Number of Products under Development for Peanut Allergy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Peanut Allergy - Pipeline by Aimmune Therapeutics, Inc., H1 2016
  • Peanut Allergy - Pipeline by AnaptysBio, Inc., H1 2016
  • Peanut Allergy - Pipeline by Array BioPharma Inc., H1 2016
  • Peanut Allergy - Pipeline by ASIT biotech s.a., H1 2016
  • Peanut Allergy - Pipeline by BioLingus AG, H1 2016
  • Peanut Allergy - Pipeline by DBV Technologies S.A., H1 2016
  • Peanut Allergy - Pipeline by HAL Allergy BV, H1 2016
  • Peanut Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Peanut Allergy Therapeutics - Recent Pipeline Updates, H1 2016
  • Peanut Allergy - Dormant Projects, H1 2016
  • Peanut Allergy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Peanut Allergy, H1 2016
  • Number of Products under Development for Peanut Allergy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top